Trump’s latest pharma deals may undermine efforts to rein in drug costs

Analysts warn that private drug deals could lower prices in Medicaid while leaving Medicare prices untouched, potentially undermining broader cost-control efforts.

• Analysts note private deals involve drugmakers lowering Medicaid prices in exchange for no Medicare price cuts